Company Analysis
Sign in

Takeda Pharmaceutical Company Limited (TAK)

NYSE: TAK · Pharmaceutical Preparations · Tokyo, JP · filing with the SEC since 2007
Full chart Alerts Compare
Grade5.7
◀ Past 7.8● Present 4.9▶ Future 4.4
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Who runs Takeda Pharmaceutical Company Limited

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Kim Julie So-Young
President and CEO. First filing Mar 2026, latest Aug 12, 2026, 1 filing in all.
Officers reporting now
17
of 31 people with a filing in the last fifteen months
Directors reporting now
14
31 people on the record since 2026
Officerssales are open-market, Nov 5, 2025 to Nov 5, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Platford Giles RichardPresident, IBUMar 2026Nov 5, 20262 · $1.7M
Bitetti Teresa MariePresident, OBUMar 2026Nov 4, 20262 · $1.8M
Duprey Lauren RusckowskiChief Transformation OfficerMar 2026Sep 15, 20262 · $1.5M
Plump Andrew StewartPresident, R&DMar 2026Sep 3, 20263 · $5.3M
Greenway Nicola Deidre PetalChief Human Resources OfficerApr 2026Aug 19, 20264 · $1.0M
Kim Julie So-YoungPresident and CEOMar 2026Aug 12, 20261 · $1.5M
Ibrahim Ramy Riad AhmedPresident, PDT BUApr 2026Aug 12, 20261 · $100,000
Pacheco Rhonda JanicePresident, U.S. Business UnitMar 2026Aug 12, 20261 · $300,000
Farajallah Awny Samaan BotrosChief Medical OfficerApr 2026Aug 12, 20261 · $200,000
Ricci GabrieleChief Data & Tech. OfficerMar 2026Aug 12, 20261 · $400,000
Furney Natalie Anne MarieGlobal General CounselMar 2026Aug 12, 20261 · $500,000
Pignagnoli Agosti MarcelloHead, Strat. & Port. DevMar 2026Aug 12, 20261 · $400,000
Shannon Elaine MaryPres., Global Supply & QualityMar 2026Aug 12, 20262 · $400,000
Miyabashira AsukaPresident, Japan Pharma B.U.Mar 2026Jul 6, 2026none
Furuta MilanoChief Financial OfficerMar 2026Jul 6, 2026none
Smoter Jennifer MarieChief Comm. & Gov. OfficerMay 2026Jul 6, 2026none
Weber Christophe PierrePresident and CEOMar 2026Apr 28, 2026none
Directorssales are open-market, Nov 5, 2025 to Nov 5, 2026
NameRoleFirst filingLatest filingSales, 12 months
Broussard Bruce DdirectorJul 2026Jul 6, 2026none
Gillis StevendirectorMar 2026Jul 6, 2026none
Iijima MasamidirectorMar 2026Jul 6, 2026none
Kimura KoichirodirectorJul 2026Jul 6, 2026none
Maraganore JohndirectorMar 2026Jul 6, 2026none
Reed Kimberly A.directorMar 2026Jul 6, 2026none
Stoffels PaulusdirectorJul 2026Jul 6, 2026none
Tsusaka MikidirectorMar 2026Jul 6, 2026none
Butel Jean LucdirectorMar 2026Mar 18, 2026none
Clark Ian TdirectorMar 2026Mar 18, 2026none
Fujimori YoshiakidirectorMar 2026Mar 18, 2026none
Hatsukawa KojidirectorMar 2026Mar 18, 2026none
Higashi EmikodirectorMar 2026Mar 18, 2026none
Orsinger Michel BrunodirectorMar 2026Mar 18, 2026none

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton TAK · research, not advice